IL17A Antibody - #DF6127

Fig. 6. F can stimulate downstream proteins in IL-17A signal pathway in the testes (n ¼ 13. Three times repetition). Statistical analysis was carried out using one-way ANOVA with Dunnett’s test. Error bars denote the mean ± s.e.m. *P < 0.05, **P < 0.01.

FIGURE 4 | The counts of Th17 cells were decreased in the LV-sponge groups, while Treg cells were increased.(D) Immunofluorescence staining of CD4+ IL-17+ cells in sections of the thyroid. The CD4+ IL-17+ cells are shown in orange (CD4+, red; IL-17+, green). Under highpower (HP) microscope, three view fields of thyroid section were randomly selected to count the number of CD4+ IL-17+ cells. Scale bar, 50 mm.

Figure 5. Effects of anti-TNFα and anti-IL-17α topical treatments onto the Phenion full-thickness skin model. H and E and immunohistological analysis of TNFα and IL17α blockers—treated SEs demonstrate reduction of epidermal thickness, accelerated differentiation process and altered syndecan-1 and -4 expression/distribution. (a) Epidermal thickness was assessed at regular intervals across the sections using ImageJ. (b) Mean epidermal thickness in microns. Three images corresponding to three independent experiments were analyzed per condition. Mean ± SD, t-student test for the comparison of two groups or multiple t-tests for more, * p < 0.05, **** p < 0.0001. (c) The biocompatibility was assayed using MTT proliferation analysis against control which was application of gelatin patch without blockers. (d) Contact sensitivity was assayed by analyzing IL-18 quantity (pg/mL) in the culture supernatant by ELISA at the same experimental conditions. (e) Evaluation of biological factors—enhanced gelatin patches using full-thickness reconstructed skin models. Immunohistological detection of syndecan-1 and -4 in reconstructed skin models after application of gelatin patches containing anti-TNFα or anti-IL17α.